outcomes and
patient quality
of life


With a legacy that spans more than 30 years in ophthalmology, Nova Eye Medical designs, develops, manufactures and markets a portfolio of proprietary glaucoma treatment technologies. Underpinning each of these technologies is our commitment to advance clinical outcomes and improve patient quality of life.

Based on the principles of angioplasty, iTrack is an implant-free glaucoma surgery that combines 360-degree catheterization with viscodilation to mechanically remove blockages and to dilate Schlemm’s canal in order to remove outflow resistance — achieving excellent clinical outcomes while also preserving the viability of subsequent glaucoma treatments.

Visit the iTrack™ website

The ground-breaking iTrack™ Advance is advancing canaloplasty to the next level. Developed out of extensive research, innovation and feedback from surgeons, iTrack™ Advance takes the established effectiveness,1,2 accuracy and reliability of the original iTrack™ canaloplasty microcatheter, and combines it with an ergonomic, easy-to-use handheld injector.

1. Gallardo MJ. 36-month effectiveness of ab-interno canaloplasty standalone versus combined with cataract surgery for the treatment of open-angle glaucoma. Ophthalmol Glaucoma. 2022 Feb 17:S2589-4196(22)00025 – 4.2.
2 Khaimi, M. A., Dvorak, J. D., & Ding, K. (2017). An analysis of 3‑year outcomes following canaloplasty for the treatment of open-angle glaucoma. Journal of ophthalmology, 2017.

Visit the iTrack™ Advance website

The Molteno3® Glaucoma Drainage Device is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe and complex glaucoma, with the added benefit of a simplified surgical procedure.

Visit the Molteno3 website

AlphaRET is a wholly owned subsidiary of Nova Eye Medical Limited, established to drive the commercial development of the 2RT™ project. 2RT™ is a breakthrough nano-pulse laser technology that stimulates the eye’s natural healing response to treat intermediate age-related macular degeneration (AMD), one of the world’s leading causes of blindness.
This website uses cookies to ensure you get the best experience on our website.
The cookies do not store any personalised information. Learn More